Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
Corporate Citizenship Report

Our FY 2020 Impact

At Terumo Blood and Cell Technologies, we aspire to provide compelling and accessible innovations that unlock the potential of blood and cells to improve patient outcomes and serve unmet medical needs. We are passionately driven to help others and to fulfill our mission of Contributing to Society through Healthcare. This is evident in the products and services we offer, and we amplify our impact through charitable giving and community involvement and by being a conscientious corporate citizen.

 

 
 

Letter from Antoinette Gawin, President and Chief Executive Officer, Terumo Blood and Cell Technologies

Since the onset of the COVID-19 pandemic, a common theme has emerged as I connect with Terumo Blood and Cell Technologies stakeholders and associates across the globe. This theme weaves through conversations with diverse individuals covering diverse topics. From discussions about cutting-edge research to caring for family members, reflection ties us together. We are frequently reflecting — personally and collectively — on how we conduct ourselves in our everyday lives and how we contribute to society through healthcare.

I am grateful to be in conversation about these reflections from customers, patients, associates and communities. And while some reflections weigh heavy with grief and loss, many offer insight and inspiration.

Think back to early 2020. We opened the year in a state of overwhelming uncertainty. And we persevered with this mantra: we will thrive, not just survive. Our priorities were clearly defined, becoming the foundation for every action we took:

  • Protect associates’ health and well-being
  • Serve our customers and patients
  • Maintain operating flexibility

Now fast-forward to 2021. We ended the fiscal year with fortitude and resolve to unlock the potential of blood and cells, in our communities and in ourselves. Along the way, we kept our priorities in focus and upheld our core values to deliver life-saving technologies, advance critical research, support associates and their families, give back to communities and create more environmentally sustainable operations.

Now fast-forward to 2021. We ended the fiscal year with fortitude and resolve to unlock the potential of blood and cells, in our communities and in ourselves. Along the way, we kept our priorities in focus and upheld our core values to deliver life-saving technologies, advance critical research, support associates and their families, give back to communities and create more environmentally sustainable operations.

In health and hope,

Antoinette Gawin
President and Chief Executive Officer
Terumo Blood and Cell Technologies
 
 
 

Our parent company, Terumo Corporation, is a signatory of the United Nations Global Compact. This signing reflects Terumo’s agreement with the Ten Principles of the compact, which are related to human rights, labor practices, the environment and anti-corruption measures.

Terumo Blood and Cell Technologies shares this commitment and has a strong business conduct and compliance program that defines how we treat our associates, customers and partners. The guidelines include acting with integrity, being truthful, complying with all applicable laws and avoiding the appearance of impropriety.

  

 
 
Download pdf summaries of this report:

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }} {{'SEARCH_MODAL_ENLABEL' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}